---
title: "Climb Bio, Inc. (CLYM.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CLYM.US.md"
symbol: "CLYM.US"
name: "Climb Bio, Inc."
industry: "Biotechnology"
---

# Climb Bio, Inc. (CLYM.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [climbbio.com](https://climbbio.com) |

## Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary mem...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.73 | 412/606 | - | - | - |
| PB | 1.93 | 161/606 | 1.03 | 0.69 | 0.42 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-25T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 88% |
| Overweight | 1 | 13% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.15 |
| Highest Target | 23.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CLYM.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CLYM.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CLYM.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.